These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38149239)

  • 41. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
    Georgiou K; Chen L; Berglund M; Ren W; de Miranda NF; Lisboa S; Fangazio M; Zhu S; Hou Y; Wu K; Fang W; Wang X; Meng B; Zhang L; Zeng Y; Bhagat G; Nordenskjöld M; Sundström C; Enblad G; Dalla-Favera R; Zhang H; Teixeira MR; Pasqualucci L; Peng R; Pan-Hammarström Q
    Blood; 2016 Jun; 127(24):3026-34. PubMed ID: 27030389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma.
    Yu T; Xu-Monette ZY; Lagoo A; Shuai W; Wang B; Neff J; Carrillo LF; Carlsen ED; Pina-Oviedo S; Young KH
    Front Immunol; 2024; 15():1335689. PubMed ID: 38348048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The biology of human lymphoid malignancies revealed by gene expression profiling.
    Staudt LM; Dave S
    Adv Immunol; 2005; 87():163-208. PubMed ID: 16102574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
    Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
    J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
    Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
    Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.
    Culpin RE; Proctor SJ; Angus B; Crosier S; Anderson JJ; Mainou-Fowler T
    Int J Oncol; 2010 Aug; 37(2):367-76. PubMed ID: 20596664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumour Microenvironment: The General Principles of Pathogenesis and Implications in Diffuse Large B Cell Lymphoma.
    Sinkarevs S; Strumfs B; Volkova S; Strumfa I
    Cells; 2024 Jun; 13(12):. PubMed ID: 38920685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.
    Gamboa-Cedeño AM; Castillo M; Xiao W; Waldmann TA; Ranuncolo SM
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1437-1448. PubMed ID: 30941572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.
    Uhl B; Prochazka KT; Pansy K; Wenzl K; Strobl J; Baumgartner C; Szmyra MM; Waha JE; Wolf A; Tomazic PV; Steinbauer E; Steinwender M; Friedl S; Weniger M; Küppers R; Pichler M; Greinix HT; Stary G; Ramsay AG; Apollonio B; Feichtinger J; Beham-Schmid C; Neumeister P; Deutsch AJ
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.
    Stokes ME; Wenzl K; Huang CC; Ortiz M; Hsu CC; Maurer MJ; Stong N; Nakayama Y; Wu L; Chiu H; Polonskaia A; Danziger SA; Towfic F; Parker J; King RL; Link BK; Slager SL; Sarangi V; Asmann YW; Novak JP; Sudhindra A; Ansell SM; Habermann TM; Hagner PR; Nowakowski GS; Cerhan JR; Novak AJ; Gandhi AK
    Nat Commun; 2024 Aug; 15(1):6790. PubMed ID: 39117654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.
    Gao HX; Nuerlan A; Abulajiang G; Cui WL; Xue J; Sang W; Li SJ; Niu J; Ma ZP; Zhang W; Li XX
    Pathol Res Pract; 2019 Sep; 215(9):152528. PubMed ID: 31324389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
    Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
    Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.
    Mahadevan D; Spier C; Della Croce K; Miller S; George B; Riley C; Warner S; Grogan TM; Miller TP
    Mol Cancer Ther; 2005 Dec; 4(12):1867-79. PubMed ID: 16373702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma.
    Ji H; Niu X; Yin L; Wang Y; Huang L; Xuan Q; Li L; Zhang H; Li J; Yang Y; An W; Zhang Q
    Cell Physiol Biochem; 2018; 45(3):951-961. PubMed ID: 29428948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression.
    Jingjing Z; Lei M; Jie Z; Sha C; Yapeng H; Weimin Z; Chunluan Y
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Aug; 393(8):1549-1558. PubMed ID: 31900516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
    Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
    Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.